ArticleFrontiers in pharmacology2025
Identification of active metabolites from
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fractures are common clinical conditions. Methods: Active metabolites in GSE were identified and isolated via column chromatography, HPLC, and LC-MS. Fracture repair was assessed by X-ray, and the outcomes were quantified with ImageJ software. Results: The results demonstrated that GSE mother liquor and its fractions GSE30, GSE50, GSE70, GSE90 promoted fracture healing. Compared to the control group, the callus area in the GSE group was increased by 1.8-fold on day 3 and by 2.0-fold on day 10. The most favorable healing effect was observed in the GSE50 group, this fraction was primarily composed of gentisin (27.6%), gentiopicroside (7.3%) and isoorientin (65.1%). A notable dose-response relationship was observed between gentisin and isoorientin concentrations in GSE and bone repair outcomes. Discussion: Our findings demonstrate that the active metabolites in GSE are potent agents for accelerating fracture repair. This suggests that gentisin, gentiopicroside and isoorientin is a promising candidate for further preclinical development, and its mechanism of action warrants deeper investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.